Ranbaxy Laboratories Ltd today said Nihon Pharmaceutical Industry Ltd, a joint venture between the company and Japan-based Nippon Chemiphar Ltd , has launched the antibiotic 'Clarithromycin' and anti-fungal 'Terbinafine' tablets in the Japanese market.
Clarithromycin has been launched in strengths of 50mg, 200mg and Terbinafine of 125mg. The products have a market size of around 400 million dollars and 300 million dollars respectively in Japan, for the above dosage forms, Ranbaxy said in a statement.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
Ranbaxy had entered the Japanese market in the year 2002 through a strategic alliance with Nippon Chemiphar, a mid sized research pharmaceutical company.
In July 2005, the JV between the two companies had introduced its first co-developed product Vogseal O.2mg and 0.3mg tablets for the treatment of diabetes.
Last year, Ranbaxy had also increased its equity stake in Nihon Pharmaceutical, making it a 50:50 joint venture between the company and Nippon Chemiphar.